Advertisement
Canada Markets open in 6 hrs 37 mins

  • S&P/TSX

    21,740.20
    -159.79 (-0.73%)
     

  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     

  • DOW

    37,735.11
    -248.13 (-0.65%)
     

  • CAD/USD

    0.7242
    -0.0011 (-0.1506%)
     

  • CRUDE OIL

    85.72
    +0.31 (+0.36%)
     

  • BTC-CAD

    87,269.91
    -4,362.93 (-4.76%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,386.60
    +3.60 (+0.15%)
     

  • RUSSELL 2000

    1,975.71
    -27.47 (-1.37%)
     

  • 10-Yr Bond

    4.6280
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,847.50
    -28.75 (-0.16%)
     

  • VOLATILITY

    19.23
    +1.92 (+11.09%)
     

  • FTSE

    7,965.53
    -30.05 (-0.38%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6824
    0.0000 (0.00%)
     
MARKETS LIVE BLOG:

STOCKS SLIP WITH MIDEAST TENSIONS, EARNINGS IN PLAY

Oil pares losses as traders anticipate Israel's response to Iranian attack

Esperion to Participate in Jefferies Healthcare Conference

Esperion Therapeutics, Inc.
·1 min read
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.

ANN ARBOR, Mich., May 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7th, 2023 at 9:00 AM ET. The Esperion management team will also be available to host 1 on 1 investor meetings.

To register for the live webcast, follow this link.

A live audio webcast can be accessed on the investor and media section of the Esperion website at investor.esperion.com. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.

ADVERTISEMENT

Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.

Esperion Contact Information: 
Investors:  
Alexis Callahan
investorelations@esperion.com
(406) 539-1762 
  
Media:  
Tiffany Aldrich  
corporateteam@esperion.com
(616) 443-8438